Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Leases: 2019-2024

Historic Operating Leases for Vanda Pharmaceuticals (VNDA) over the last 6 years, with Dec 2024 value amounting to $4.9 million.

  • Vanda Pharmaceuticals' Operating Leases fell 37.68% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 37.68%. This contributed to the annual value of $4.9 million for FY2024, which is 47.43% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Operating Leases stood at $4.9 million for FY2024, which was down 47.43% from $9.4 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Operating Leases ranged from a high of $13.6 million in FY2020 and a low of $4.9 million during FY2024.
  • For the 3-year period, Vanda Pharmaceuticals' Operating Leases averaged around $8.5 million, with its median value being $9.4 million (2023).
  • Data for Vanda Pharmaceuticals' Operating Leases shows a maximum YoY slumped of 47.43% (in 2024) over the last 5 years.
  • Vanda Pharmaceuticals' Operating Leases (Yearly) stood at $13.6 million in 2020, then decreased by 9.17% to $12.4 million in 2021, then fell by 9.91% to $11.1 million in 2022, then declined by 15.59% to $9.4 million in 2023, then crashed by 47.43% to $4.9 million in 2024.